Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 7958-7964

  Woo, Michelle M M ^a   Alkushi, Abdulmohsen ^b   Verhage, Harold G ^c   Magliocco, Anthony M ^d   Leung, Peter C K ^a   Gilks, C Blake ^b   Auersperg, Nelly ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GLYCOPROTEIN; OVIDUCT SPECIFIC GLYCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; ENDOMETRIAL DISEASE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OVIDUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; RECEPTORS, ESTROGEN; SURVIVAL RATE; UP-REGULATION;

EID: 9744262529     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1261     Document Type: Article

References (35)

1. Rapisarda JJ, Mavrogianis PA, O'Day-Bowman MB, Fazleabas AT, Verhage HG. Immunological characterization and immunocytochemical localization of an oviduct-specific glycoprotein in the human. J Clin Endocrinol Metab 1993;76:1483-8.
2. Arias EB, Verhage HG, Jaffe RC. Complementary deoxyribonucleic acid cloning and molecular characterization of an estrogen-dependent human oviductal glycoprotein. Biol Reprod 1994;51:685-94.
3. O'Day-Bowman MB, Mavrogianis PA, Fazleabas AT, Verhage HG. A human oviduct-specific glycoprotein: synthesis, secretion, and localization during the menstrual cycle. Microsc Res Tech 1995;32:57-69.
4. Boice ML, McCarthy TJ, Mavrogianis PA, Fazleabas AT, Verhage HG. Localization of oviductal glycoproteins within the zona pellucida and perivitelline space of ovulated ova and early embryos in baboons (Papio anubis). Biol Reprod 1990;43:340-6.
5. Boatman DE, Magnoni GE. Identification of a sperm penetration factor in the oviduct of the golden hamster. Biol Reprod 1995;52:199-207.
6. O'Day-Bowman MB, Mavrogianis PA, Reuter LM, Johnson DE, Fazleabas AT, Verhage HG. Association of oviduct-specific glycoproteins with human and baboon (Papio anubis) ovarian oocytes and enhancement of human sperm binding to human hemizonae following in vitro incubation. Biol Reprod 1996;54:60-9.
7. Schmidt A, Mavrogianis PA, O'Day-Bowman MB, Jaffe RC, Verhage HG. Characterization of antibodies generated against a conserved portion of oviductal glycoprotein (OGP) and endogenous hamster OGP and their ability to decrease sperm binding to the zona pellucida in vitro. Am J Reprod Immunol 1997;38:377-83.
8. Leese HJ, Tay JI, Reischl J, Downing SJ. Formation of fallopian tubal fluid: role of a neglected epithelium. Reproduction 2001;121:339-46.
9. Woo MM, Gilks CB, Verhage HG, Longacre TA, Leung PC, Auersperg N. Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. Gynecol Oncol 2004;93:315-9.
10. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA - Cancer J Clin 2004;54:8-29.
11. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213-23.
12. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. New York: Springer-Verlag; 1994. p. 441.
13. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000;77:55-65.
14. Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998;69:69-73.
15. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16:600-10.
16. Sivridis E, Giatromanolaki A. Prognostic aspects on endometrial hyperplasia and neoplasia. Virchows Arch 2001;439:118-26.
17. Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol (Lond.) 2002;55:326-31.
18. Longacre TA, Chung MH, Jensen DN, Hendrickson MR. Proposed criteria for the diagnosis of well-differentiated endometrial carcinoma. A diagnostic test for myoinvasion. Am J Surg Pathol 1995;19:371-406.
19. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998;22:1012-9.
20. Dietel M. The histological diagnosis of endometrial hyperplasia. Is there a need to simplify? Virchows Arch 2001;439:604-8.
21. Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol 2000;13:309-27.
22. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-4.
23. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003;442:271-7.
24. Lok IH, Briton-Jones CM, Yuen PM, Haines CJ. Variable expression of oviductin mRNA at different stages of human reproductive cycle. J Assist Reprod Genet 2002;19:569-76.
25. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
26. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
27. Tanaka M, Kyo S, Kanaya T, et al. Evidence of the monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium. Am J Pathol 2003;163:295-301.
28. Kanaya T, Kyo S, Maida Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 2003;22:2352-60.
29. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst (Bethesda) 2000;92:924-30.
30. Auersperg N, Woo MMM. Development and differentiation of ovarian surface epithelium: cues for the basis of its malignant potential. In: Leung PCK, Adashi EY, editors. The ovary. San Diego: Elsevier Academic Press; 2004. p. 580-90.
31. Agarwal A, Yeung WS, Lee KF. Cloning and characterization of the human oviduct-specific glycoprotein (HuOGP) gene promoter. Mol Hum Reprod 2002;8:167-75.
32. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-13.
33. Uchikawa J, Shiozawa T, Shih HC, et al. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer (Phila.) 2003;98:2207-13.
34. Sasaki M, Kotcherguina L, Dharia A, Fujimoto S, Dahiya R. Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res 2001;61:3262-6.
35. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science (Wash. DC) 2002;295:2465-8.